LON:MXC Argent BioPharma (MXC) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Argent BioPharma Stock (LON:MXC) 30 days 90 days 365 days Advanced Chart Get Argent BioPharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume264 shsAverage Volume26,353 shsMarket Capitalization£9.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. In addition, the company provides Irnican that is in preclinical phase for the tetrahydrocannabinol, as well as offers ArtemiC and non-pharma products. Further, it offers consulting services, including clinical research services. MGC Pharmaceuticals Limited was founded in 2014 and is based in Subiaco, Australia. Read More Receive MXC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Argent BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address MXC Stock News HeadlinesRunners of the Week: Kaili, Magnetite Mines, Argent Biopharma, OctavaAugust 22 at 8:22 AM | msn.comArgent BioPharma Expands with Strategic Acquisition of AusCann AssetsAugust 19, 2025 | msn.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | Porter & Company (Ad)Argent starts EU-GMP cannabinoid supply for drug resistant epilepsy at Slovenia’s largest hospitalJuly 8, 2025 | msn.comArgent and AusCann partner to accelerate cannabinoid pharma developmentApril 15, 2025 | msn.comArgent BioPharma Prepares for Major Capital RaisingJanuary 2, 2025 | tipranks.comArgent BioPharma to Delist From London Stock Exchange, Mulls U.S. ListingNovember 29, 2024 | marketwatch.comArgent BioPharma Ltd (RGT)May 9, 2024 | investing.comSee More Headlines MXC Stock Analysis - Frequently Asked Questions How do I buy shares of Argent BioPharma? Shares of MXC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Argent BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Argent BioPharma investors own include Rolls-Royce Holdings plc (RR), Argo Blockchain (ARB), AutoZone (AZO), BP (BP), Chaarat Gold (CGH), Diageo (DGE) and EQTEC (EQT). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPetroleum And Natural Gas Current SymbolLON:MXC CIKN/A Webmgcpharma.com.au Phone61-8-6555-2950FaxN/AEmployees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£17.02 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-58.96% Debt Debt-to-Equity Ratio1,436.12 Current Ratio0.75 Quick RatioN/A Sales & Book Value Annual Sales£1.32 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueGBX 4 per share Price / BookN/AMiscellaneous Outstanding Shares43,850,000Free FloatN/AMarket Cap£9.65 million OptionableNot Optionable Beta1.03 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (LON:MXC) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Argent BioPharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Argent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.